Monoclonal antibody directed against CXCR5

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9534054
APP PUB NO 20160115235A1
SERIAL NO

14787478

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to monoclonal antibodies against human CXCR5 and to their use in the treatment of autoimmune or inflammatory diseases, as well as cancers.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ARES TRADING S AZONE INDSUTRIELLE DE L'OURIETTAZ AUBONNE CH-1170

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
An, Qi Nashua, US 209 1800
Bradfield, Paul Geneva, CH 4 5
Iffland, Christel Arlington, US 12 198
Leger, Olivier Saint-Sixt, FR 68 1083
Nastri, Horacio G Armonk, US 23 342
Power, Christine Thoiry, FR 49 192

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 3, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00